To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
3,557 Current news from the ressort productsrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
BioMed X announced the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease. BioMed X received a milestone payment and the results of the project were transferred to AbbVie. The BioMed X team ...
Modern medicine is looking for markers that provide early warning of complex diseases. In its quest to discover these “biomarkers”, the ETH spinoff Scailyte has developed software capable of analysing millions of single cells very efficiently. The search for biomarkers is currently one of the ...
Nordic Nanovector ASA announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma (NHL). The same patent has also been issued in ...
BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first FDA approval for an anti-PD-L1 therapy as part of a ...
An economically significant process intensification for the efficient enzymatic synthesis of (1S,2R)-1-(methoxycarbonyl) cyclohex-4-ene-2-carboxylic acid was achieved by a careful adaption of the reaction mode to minimize mass transfer limitations. (1S,2R)-1-(methoxycarbonyl) ...
Drug candidate PRI-002 has successfully completed Phase I of clinical research
The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will ...
The Fraunhofer Institute for Production Technology IPT in Aachen has developed a high-speed microscope for quality control of large-area objects for the semiconductor and electronics industries or for rapid testing of biological samples. The microscope digitizes samples with up to 500 frames per ...
Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract. Janssen has initiated a phase 1b proof-of-concept clinical ...
Are You Ready for Lab Samples to be Delivered by Drones?
Hudson Robotics, Inc. announced a collaboration with Physical Sciences Inc. (PSI) to bring drone technology to life science laboratories for sample handling. Specifically, microplates containing samples or reagents will be delivered directly to instruments and automated workcells to perform ...
Generative modelling AI technology enables rapid and cost-effective design of novel drugs
Merck announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. “This agreement is another illustration of how we aim to ...